Pharmaceutical care for the HIV-negative patient with disseminated <italic style="font-style: italic">Talaromyces marneffei</italic> osteomyelitis complicated by pulmonary tuberculosis

ZHANG Qinghua; HE Liting

doi:10.6039/j.issn.1001-0408.2025.16.19

您当前的位置：

首页 >

文章列表页 >

Pharmaceutical care for the HIV-negative patient with disseminated Talaromyces marneffei osteomyelitis complicated by pulmonary tuberculosis

更新时间：2025-09-25

- Pharmaceutical care for the HIV-negative patient with disseminated Talaromyces marneffei osteomyelitis complicated by pulmonary tuberculosis
- ZHONGGUO YAOFANG Vol. 36, Issue 16, Pages: 2062-2066(2025)
- 作者机构：
  
  江门市中心医院药学部，广东江门　529000
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.16.19
  CLC： S945.1+3;R969.3
- Received：06 May 2025，
  
  Revised：2025-07-28，
  
  Accepted：29 July 2025，
  
  Published：30 August 2025
- 稿件说明：
移动端阅览
张清华,何丽庭.HIV阴性播散型马尔尼菲篮状菌骨髓炎合并肺结核患者的药学监护[J].中国药房,2025,36(16):2062-2066.

ZHANG Qinghua,HE Liting.Pharmaceutical care for the HIV-negative patient with disseminated Talaromyces marneffei osteomyelitis complicated by pulmonary tuberculosis[J].ZHONGGUO YAOFANG,2025,36(16):2062-2066.
张清华,何丽庭.HIV阴性播散型马尔尼菲篮状菌骨髓炎合并肺结核患者的药学监护[J].中国药房,2025,36(16):2062-2066. DOI： 10.6039/j.issn.1001-0408.2025.16.19.

ZHANG Qinghua,HE Liting.Pharmaceutical care for the HIV-negative patient with disseminated Talaromyces marneffei osteomyelitis complicated by pulmonary tuberculosis[J].ZHONGGUO YAOFANG,2025,36(16):2062-2066. DOI： 10.6039/j.issn.1001-0408.2025.16.19.

摘要

目的

为人类免疫缺陷病毒（HIV）阴性患者播散型马尔尼菲篮状菌（TM）骨髓炎合并肺结核抗感染治疗的药学监护提供参考。

方法

临床药师参与1例HIV阴性播散型TM骨髓炎合并肺结核患者的治疗全过程，系统评估患者临床症状、体征及检验、影像学结果后，协助医师制定治疗方案及完善诊断，建议给予两性霉素B胆固醇硫酸酯复合物抗真菌治疗和完善结核菌素试验及痰涂片抗酸染色，实时监护患者的临床表现及检验结果；及时发现患者血钾降低，分析原因后，先后建议口服和静脉补钾，并调整治疗方案（改用伊曲康唑，联合异烟肼+利福平+吡嗪酰胺+乙胺丁醇四联抗结核），同时建议监测伊曲康唑血药浓度。此外，临床药师还对患者进行了系统的用药和健康教育。

结果

医师采纳临床药师的建议，患者治疗后好转出院。临床药师随访1年患者病情治愈，无不良反应发生。

结论

两性霉素B胆固醇硫酸酯复合物是HIV阴性患者播散型TM骨髓炎的有效治疗药物，延长疗程可防止复发；用药期间临床药师需加强药学监护，保障患者用药安全。

Abstract

OBJECTIVE

To provide references for pharmaceutical care in the anti-infective treatment of disseminated

Talaromyces marneffei

（TM）osteomyelitis complicated with pulmonary tuberculosis in a human immunodeficiency virus （HIV）-negative patient.

METHODS

Clinical pharmacists participated in the entire treatment process of a HIV-negative patient with disseminated TM osteomyelitis complicated by pulmonary tuberculosis. The pharmacist assisted the clinician in formulating an individualized treatment plan and improving the diagnosis based on the patient’s clinical symptoms， signs， laboratory tests， and imaging findings. Recommendations included the use of amphotericin B cholesteryl sulfate complex for antifungal therapy， the completion of a tuberculin skin test and sputum acid-fast bacilli test. The pharmacist monitored the patient’s clinical manifestations and laboratory results in real time. Upon timely detection of hypokalemia in the patient， after analyzing the causes， oral and then intravenous potassium supplementation was sequentially recommended， along with adjustments to the treatment plan （switching to itraconazole and combining it with a four-drug antituberculosis regimen of isoniazid+rifampicin+pyrazinamide+ethambutol）. Meanwhile， monitoring of itraconazole blood concentration was also advised. Additionally， the clinical pharmacist closely monitored the patient’s medication adherence and provided medication education.

RESULTS

The clinicians accepted the clinical pharmacist’s recommendations. The patient improved after treatment and was discharged. One-year follow-up showed that the patient was cured without adverse reactions.

CONCLUSIONS

Amphotericin B cholesteryl sulfate complex is an effective therapeutic agent for disseminated TM osteomyelitis in HIV-negative patients. Prolonging the course of treatment can prevent recurrence. During therapy， clinical pharmacists should strengthen pharmaceutical care as well as provide medication and health education to ensure patient safety.

关键词

Keywords

references

中华医学会感染病学分会艾滋病丙型肝炎学组 . 艾滋病合并马尔尼菲篮状菌病诊疗专家共识：2024年更新版 [J ] . 中国艾滋病性病， 2024 ， 30 （ 6 ）： 563 - 572 .

CAO C W ， XI L Y ， CHATURVEDI V . Talaromycosis（penicilliosis）due to Talaromyces （ Penicillium ） marneffei ：insights into the clinical trends of a major fungal disease 60 years after the discovery of the pathogen [J ] . Mycopathologia ， 2019 ， 184 （ 6 ）： 709 - 720 .

QIU Y ， ZHANG J Q ， LIU G N ， et al . Retrospective analysis of 14 cases of disseminated Penicillium marneffei infection with osteolytic lesions [J ] . BMC Infect Dis ， 2015 ， 15 ： 47 .

PRUKSAPHON K ， NOSANCHUK J D ， RATANABANANGKOON K ， et al . Talaromyces marneffei infection：virulence，intracellular lifestyle and host defense mechanisms [J ] . J Fungi（Basel）， 2022 ， 8 （ 2 ）： 200 .

WANG F ， HAN R H ， CHEN S . An overlooked and underrated endemic mycosis-talaromycosis and the pathogenic fungus Talaromyces marneffei [J ] . Clin Microbiol Rev ， 2023 ， 36 （ 1 ）： e0005122 .

“十三五”国家科技重大专项艾滋病机会性感染课题组 . 艾滋病合并马尔尼菲篮状菌病临床诊疗的专家共识 [J ] . 西南大学学报（自然科学版）， 2020 ， 42 （ 7 ）： 61 - 75 .

GUO J ， NING X Q ， DING J Y ， et al . Anti-IFN-γ autoantibodies underlie disseminated Talaromyces marneffei infections [J ] . J Exp Med ， 2020 ， 217 （ 12 ）： e20190502 .

徐雪花，樊慧峰，卢根 . 儿童马尔尼菲青霉菌感染的诊治进展 [J ] . 中华实用儿科临床杂志， 2022 ， 37 （ 6 ）： 474 - 477 .

中国医药教育协会真菌病专业委员会 . 两性霉素B不同剂型临床合理应用多学科专家共识： 2024版 [J ] . 中华内科杂志， 2024 ， 63 （ 3 ）： 230 - 257 .

中国医药教育协会感染疾病专业委员会 . 两性霉素B脱氧胆酸盐临床合理应用专家共识：2022 [J ] . 中华医学杂志， 2023 ， 103 （ 16 ）： 1173 - 1183 .

STOVER K R ， CLEARY J D . Antifungal penetration and distribution into organs and tissue [J ] . Curr Fungal Infect Rep ， 2020 ， 14 （ 3 ）： 279 - 288 .

赵东陆，马军，黄晓军，等 . 注射用两性霉素B胆固醇硫酸酯复合物用药指导原则 [J ] . 临床血液学杂志， 2022 ， 35 （ 5 ）： 303 - 308 .

GÓMEZ-LÓPEZ A . Antifungal therapeutic drug monito-ring：focus on drugs without a clear recommendation [J ] . Clin Microbiol Infect ， 2020 ， 26 （ 11 ）： 1481 - 1487 .

中国医药教育协会感染疾病专业委员会 . 抗菌药物药代动力学/药效学理论临床应用专家共识 [J ] . 中华结核和呼吸杂志， 2018 ， 41 （ 6 ）： 409 - 446 .

HUANG Z W ， YU J C ， WANG J J ， et al . Pharmacokine-tics and safety of single-dose amphotericin B colloidal dispersion in healthy Chinese subjects and population pharmacokinetic/pharmacodynamic analysis to inform clinical efficacy in invasive infections caused by Candida albicans [J ] . Clin Ther ， 2021 ， 43 （ 11 ）： 1921 - 1933 .

AGBABIAKA T B ， SAVOVIĆ J ， ERNST E . Methods for causality assessment of adverse drug reactions：a systema-tic review [J ] . Drug Saf ， 2008 ， 31 （ 1 ）： 21 - 37 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Expert consensus on rational medication management of targeted PI3K/Akt/mTOR inhibitors in breast cancer

Individualized treatment and pharmaceutical care for breast cancer complicated with chronic kidney disease

Pharmaceutical care of anti-infective treatment for a case of pulmonary infection due to Alternaria alternata after renal transplantation

Anticoagulation therapy analysis and pharmaceutical care for a breast cancer patient with pulmonary thromboembolism accompanied by multiple comorbidities

Pharmaceutical care for a patient with empagliflozin-induced euglycemic diabetic ketoacidosis

Related Author

Writing Group of Expert Consensus on Rational Medication Management of Targeted PI3K/Akt/mTOR Inhibitors in Breast Cancer

任天舒

赵庆春

ZHANG Ming

YU Lu

WU Xudong

WANG Yanping

GAO Shan

Related Institution

Dept. of Internal Medicine， Zhonggongmiao Community Hospital of Ningbo Yinzhou District No.2 Hospital Medical Community

Dept. of Clinical Pharmacy， Ningbo Yinzhou District No.2 Hospital

Dept. of Pharmacy， Tangshan Maternal and Child Health Hospital

Dept. of Pharmacy， Tianjin Anding Hospital

Dept. of Pharmacy， Tianjin First Central Hospital

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰

Pharmaceutical care for the HIV-negative patient with disseminated Talaromyces marneffei osteomyelitis complicated by pulmonary tuberculosis

DOI：10.6039/j.issn.1001-0408.2025.16.19

摘要

Abstract

关键词

Keywords

references